Treatment of sickle cell pain crisis. A clinical trial of diflunisal (Dolobid)* * Dolobid - Merck, Sharp, and Dohme.
The value of diflunisal (Dolobid) *, an anti-inflammatory/analgesic drug, as an adjunct to the treatment of painful sickle cell crisis was investigated in a five-day, double-blind, placebo-controlled, randomized study. All patients were hospitalized and received routine supportive care. Intramuscular injections of meperidine and hydroxyzine were given every 3-4 hours on request. In addition patients received either diflunisal 500 mg by mouth every 12 hours after a 1000 mg loading dose or a placebo given on the same schedule. Pain score was measured on a categorical pain scale. Both groups required a similar total amount of meperidine and hydroxyzine over the five-day study period and stayed in hospital for a similar length of time. Furthermore pain intensity difference scores (derived by subtracting the patients' daily pain intensity score from the pain score at entry) did not differ in the two groups of patients. It is concluded from this study that diflunisal is not effective in relieving the pain associated with sickle cell crises requiring hospitalization. © 1988.
Perlin, Elliott; Finke, Helga; Castro, Oswaldo; Bang, Ki Moon; Rana, Sohail; Taylor, Robert; Addo, Koran; Adir, Joseph; Miller, Ann K.; Elemihe, Uzomah N.; and Curry, Clarence E., "Treatment of sickle cell pain crisis. A clinical trial of diflunisal (Dolobid)* * Dolobid - Merck, Sharp, and Dohme." (1988). The Center For Sickle Cell Disease Faculty Publications. 271.